Alzheon Announces Notice of Allowance for US Patent for its Lead Drug Candidate ALZ-801 in Clinical Development for Alzheimer’s Disease

Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and ageing, has announced that the United States Patent and Trademark Office (US PTO) has issued a notice of allowance for the U.S. Patent Application Number 11/871,639, entitled “Methods, Compounds, Compositions and Vehicles for Delivering 3-Amino-1-Propanesulfonic Acid.” 

The allowed claims are directed to Alzheon’s lead therapeutic candidate ALZ-801, and protect the ALZ-801 compound, pharmaceutical compositions containing ALZ-801, as well as methods of treating Alzheimer’s disease using ALZ-801. Alzheon is currently advancing ALZ-801 into a confirmatory pivotal Phase 2/3 study in Alzheimer’s disease patients positive for ε4 allele of the apolipoprotein E.

Alzheon’s intellectual property represented in this patent is derived from the company’s acquisition of ALZ-801 and related assets in October 2013 as well as additional inventions by the company. To support its business and strategy, Alzheon has assembled and continues to build a strong intellectual property portfolio for the treatment of Alzheimer’s disease and other diseases of the central nervous system.

“We are very pleased to obtain this patent allowance for our lead clinical candidate. The allowance of this broad, foundational composition of matter patent further validates the innovative nature of our technology and the proprietary nature of our therapeutic approach and product candidate ALZ-801,” said Martin Tolar, MD, PhD, Founder, President and Chief Executive Officer of Alzheon. “Alzheon is well positioned with a strong intellectual property estate as we execute on our growth-oriented strategy to advance Alzheon as a world-leading Alzheimer’s company.”